Summary of Key Points Core Viewpoint - The recent block trade of Chahua Co., Ltd. indicates significant trading activity, with a notable decline in stock price and net outflow of funds, suggesting potential investor concerns [2]. Trading Activity - On September 25, a block trade occurred involving 101,000 shares of Chahua Co., with a transaction value of 2.5442 million yuan and a trading price of 25.19 yuan per share [2]. - Over the past three months, Chahua Co. has recorded a total of 7 block trades, amounting to 102 million yuan [2]. Stock Performance - The closing price of Chahua Co. on the same day was 25.19 yuan, reflecting a decrease of 6.57% [2]. - The stock's turnover rate was 4.50%, with a total trading volume of 280 million yuan for the day [2]. - There was a net outflow of 41.2566 million yuan in main funds, and the stock has seen a cumulative decline of 7.08% over the past five days, with total fund outflow of 43.4257 million yuan [2]. Company Background - Chahua Modern Household Products Co., Ltd. was established on March 3, 1997, with a registered capital of 24.182 million yuan [2].

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. and its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. have received drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution from the National Medical Products Administration of China [1][4]. Group 1: Drug Registration Details - Oseltamivir Phosphate Dry Suspension is approved for the treatment of influenza A and B in adults and children aged 2 weeks and older, and for prevention in individuals aged 1 year and older [2][3]. - The drug is classified as a Class 3 chemical drug and has been included in the National Basic Medical Insurance and Essential Drug List [2][3]. - The company has invested a total of RMB 13.41 million in the research and development of Oseltamivir Phosphate Dry Suspension [3]. Group 2: Lactulose Oral Solution - Lactulose Oral Solution is approved for the treatment of chronic functional constipation and is classified as a Class 4 chemical drug [4][5]. - The product has also been included in the National Basic Medical Drug Directory [6]. - The company has invested a total of RMB 3.31 million in the research and development of Lactulose Oral Solution [7]. Group 3: Clinical Trial Approval - The company has received approval for clinical trials of Pediatric Lung Heat Cough and Asthma Granules, which will be tested for use in treating influenza in children [11]. - This clinical trial is based on an existing product and aims to enhance its therapeutic indications [11]. - Further regulatory approvals are required before the product can be marketed [11].

Core Viewpoint - ST HULUWA (605199) and its wholly-owned subsidiary Guangxi Weiwei have received drug registration certificates from the National Medical Products Administration for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution [1] Group 1 - The company has obtained approval for the clinical trial of Pediatric Lung Heat Cough and Asthma Granules from the National Medical Products Administration [1]

Group 1 - ST HuLuWa announced the approval of drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution by the National Medical Products Administration [1] - The company's revenue composition for the year 2024 is projected to be 100% from the pharmaceutical manufacturing industry [1] - As of the report, ST HuLuWa has a market capitalization of 3.7 billion yuan [1] Group 2 - The announcement highlights a significant breakthrough in drug development, recognized by both Chinese and American authorities for its therapeutic efficacy [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）及全资子公司广西维威 制药有限公司（以下简称"广西维威"）近日分别收到国家药品监督管理局（以下简 称"国家药监局"）核准签发的关于磷酸奥司他韦干混悬剂、乳果糖口服溶液的《药 品注册证书》。现将有关情况公告如下： 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-067 海南葫芦娃药业集团股份有限公司 关于公司及全资子公司获得药品注册证书的公告 一、磷酸奥司他韦干混悬剂 （一）药品基本情况 药物名称：磷酸奥司他韦干混悬剂 剂型：干混悬剂 注册分类：化学药品 3 类 规格：0.36g（按 C₁₆H₂₈N₂O₄计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2303053 药品批准文号：国药准字 H20255455 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 （二）药品研发及相关 磷酸奥司他韦干混悬剂的适应症为：1．用于 ...

Group 1 - ST HuLuWa (605199.SH) announced the approval of drug registration certificates for Oseltamivir Phosphate Dry Suspension and Lactulose Oral Solution by the National Medical Products Administration [1] - Oseltamivir Phosphate Dry Suspension is indicated for the treatment of influenza A and B in adults and children aged 2 weeks and older, with a recommendation to use within 48 hours of symptom onset [1] - Lactulose Oral Solution is indicated for chronic functional constipation [1]

Group 1 - The company ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for clinical trials of its pediatric product, "Pediatric Lung Heat Cough and Wheezing Granules," intended for use in treating influenza in children [1]

Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for clinical trials of its pediatric lung heat cough and asthma granules, indicating a significant step in the development of this product [1] Company Summary - The clinical trial approval pertains to the improved formulation of the already marketed "Pediatric Lung Heat Cough and Asthma Granules" (National Drug Approval Number Z20033152) [1] - The new formulation aims to expand the therapeutic indications to include "lung heat syndrome caused by influenza" in addition to its original functions [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-068 海南葫芦娃药业集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收 到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于 小儿肺热咳喘颗粒的《药物临床试验批准通知书》，同意本品开展临 床试验。现将有关情况公告如下： 一、药品基本情况 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，2025 年 7 月 2 日受理的小儿肺热咳喘颗粒临床试验申请符合药 品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品 开展用于儿童流行性感冒的临床试验。 二、药品研发及相关情况 本次申请进行的临床试验是在公司持有的已上市的"小儿肺热咳 喘颗粒"（国药准字 Z20033152）基础上进行改良研制，在原功能主 治的基础上增加"流行性感冒属热毒袭肺证者"。 根据国家药监局关于发布《中药注册分类及申报资料要求》的通 告（2020 年第 68 ...

Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for clinical trials of its pediatric lung heat cough and asthma granules, indicating a significant step in product development and potential market expansion [1] Company Summary - The clinical trial approval pertains to the improvement and development of the existing product "Pediatric Lung Heat Cough and Asthma Granules" (National Drug Approval Number Z20033152) [1] - The new formulation aims to enhance the original function by adding treatment for "lung heat syndrome caused by influenza" [1]